Literature DB >> 25372999

Confidence Interval Estimation for Sensitivity to the Early Diseased Stage Based on Empirical Likelihood.

Tuochuan Dong1, Lili Tian1.   

Abstract

Many disease processes can be divided into three stages: the non-diseased stage: the early diseased stage, and the fully diseased stage. To assess the accuracy of diagnostic tests for such diseases, various summary indexes have been proposed, such as volume under the surface (VUS), partial volume under the surface (PVUS), and the sensitivity to the early diseased stage given specificity and the sensitivity to the fully diseased stage (P2). This paper focuses on confidence interval estimation for P2 based on empirical likelihood. Simulation studies are carried out to assess the performance of the new methods compared to the existing parametric and nonparametric ones. A real dataset from Alzheimer's Disease Neuroimaging Initiative (ADNI) is analyzed.

Entities:  

Keywords:  Diagnostic tests; Empirical likelihood; The sensitivity to the early diseased stage.

Mesh:

Substances:

Year:  2014        PMID: 25372999      PMCID: PMC5540368          DOI: 10.1080/10543406.2014.971173

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  20 in total

1.  Comparing three-class diagnostic tests by three-way ROC analysis.

Authors:  S Dreiseitl; L Ohno-Machado; M Binder
Journal:  Med Decis Making       Date:  2000 Jul-Sep       Impact factor: 2.583

2.  Ordered multiple-class ROC analysis with continuous measurements.

Authors:  Christos T Nakas; Constantin T Yiannoutsos
Journal:  Stat Med       Date:  2004-11-30       Impact factor: 2.373

3.  Empirical likelihood-based confidence intervals for the sensitivity of a continuous-scale diagnostic test at a fixed level of specificity.

Authors:  Angela E Davis; Bing-Yi Jing
Journal:  Stat Methods Med Res       Date:  2009-08-04       Impact factor: 3.021

4.  The meaning and use of the volume under a three-class ROC surface (VUS).

Authors:  Xin He; Eric C Frey
Journal:  IEEE Trans Med Imaging       Date:  2008-05       Impact factor: 10.048

5.  Three-way ROCs.

Authors:  D Mossman
Journal:  Med Decis Making       Date:  1999 Jan-Mar       Impact factor: 2.583

6.  Three-class ROC analysis--toward a general decision theoretic solution.

Authors:  Xin He; Brandon D Gallas; Eric C Frey
Journal:  IEEE Trans Med Imaging       Date:  2009-10-30       Impact factor: 10.048

7.  A regression approach to ROC surface, with applications to Alzheimer's disease.

Authors:  Jialiang Li; Andrew Xiaohua Zhou; Jason P Fine
Journal:  Sci China Math       Date:  2012-08       Impact factor: 1.331

8.  Statistical approaches to the analysis of receiver operating characteristic (ROC) curves.

Authors:  B J McNeil; J A Hanley
Journal:  Med Decis Making       Date:  1984       Impact factor: 2.583

9.  Accuracy and cut-off point selection in three-class classification problems using a generalization of the Youden index.

Authors:  Christos T Nakas; Todd A Alonzo; Constantin T Yiannoutsos
Journal:  Stat Med       Date:  2010-12-10       Impact factor: 2.373

10.  Confidence interval estimation of the difference between two sensitivities to the early disease stage.

Authors:  Tuochuan Dong; Le Kang; Alan Hutson; Chengjie Xiong; Lili Tian
Journal:  Biom J       Date:  2013-11-22       Impact factor: 2.207

View more
  2 in total

Review 1.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

2.  Empirical likelihood confidence interval for sensitivity to the early disease stage.

Authors:  Husneara Rahman; Yichuan Zhao
Journal:  Pharm Stat       Date:  2021-12-27       Impact factor: 1.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.